Latest news
Stay in the know about our progress, and visit our Newsroom
A Galapagos company
Generating novel antibody-based biological therapeutics
Abound Bio is a US company whose mission is to generate novel antibody-based biological therapeutics to meet unmet medical needs in the fields of cancer and infectious disease. Galapagos acquired Abound Bio in 2022.
In 2022, Abound Bio was acquired by Galapagos. Since then, we have been united around a single purpose: to transform patient outcomes through life-changing science and innovation for more years of life and quality of life.
As a result, we will be sharing all company updates, news, and insights on Galapagos’ website.
Stay in the know about our progress, and visit our Newsroom
Read more about how we are #LivingInnovation in our stories
Looking for information about our company, our stock and our financials?